Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on developing a diversified pipeline of GLP-1 therapies for obesity treatment. Headquartered in Waltham, Massachusetts, the company advances multiple clinical programs including ribupatide, its lead product candidate that functions as a once-weekly injectable GLP-1/GIP receptor dual agonist peptide currently in global Phase 3 trials. The company also develops oral and injectable formulations targeting various stages of obesity treatment, including KAI-7535, an oral small-molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera holds exclusive worldwide rights outside of China, Hong Kong, Macau, and Taiwan for its therapeutic candidates licensed from Jiangsu Hengrui Pharmaceuticals. The company recently completed its initial public offering and operates within the healthcare biotechnology sector, addressing obesity as a chronic progressive disease affecting over one billion people globally.
$18.59
$0.28 (-1.48%)
EOD Aug 12, 2026
Negative free cash flow of -$122M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$149M
Op. Margin
—
ROIC
-1163.29%
Cash Flow & Balance Sheet
FCF (TTM)
-$122M
Op. Cash Flow (TTM)
-$120M
Net Debt
-$535M
Net Cash Position
Cash & Equiv.
$546M
Continue Research
Kailera Therapeutics (KLRA)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Kailera Therapeutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Kailera Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,163.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh KLRA's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.